(P30-011-25) AG1 Improves Biomarkers of Nutrient Status: A Randomized Controlled Trial

Objectives: Nutrient inadequacy is a serious public health risk in the US as the underconsumption of key nutrients can lead to suboptimal levels of nutrient biomarkers. The objective of this study was to evaluate the efficacy of 12 weeks of daily AG1^® consumption on blood biomarkers of key vitamins and minerals in healthy adults.

Methods: A triple-blind, randomized, placebo-controlled parallel trial was conducted in 120 healthy adults (41 ± 10 y) with suboptimal fruit and vegetable intakes, mirroring the standard US diet. Participants were instructed to maintain their usual diet and were randomized to receive either AG1^® (13 g daily) or a placebo (maltodextrin, matched for taste and appearance) mixed in 8-10oz of water for a duration of 12 weeks. A fasted, resting blood draw was completed before (PRE) and following (POST) 12-weeks of daily supplementation for assessment of nutrient status markers. The ASA24<sup>® dietary assessment tool was used to assess dietary intake at PRE and POST to ensure participants maintained their normal diet.

Results: Of the 120 enrolled participants, 105 adults completed PRE and POST blood testing (41.4 ± 10 y; n = 77 F) of circulating vitamin C, serum folate, red blood cell folate, homocysteine, and zinc concentrations. Two-way (treatment group x time) ANOVAs revealed significant (p < 0.05) time by treatment group effects in which there were significant increases in the AG1 group compared to placebo for vitamin C (33% increase; p < 0.001), serum folate (26% increase; p < 0.001), red blood cell folate (6% increase; p < 0.001), and a significant decrease in homocysteine (10% decrease, p = 0.014) following the 12 week intervention. Neither the AG1 nor the placebo group demonstrated improvements in serum zinc concentrations between PRE and POST testing (p > 0.05). Additionally, ASA24® dietary analysis confirmed no differences p > 0.05) in dietary intake of vitamin C, folate, or zinc between groups over the 12-week intervention apart from the nutrient content of the AG1 supplement in the AG1 group. Furthermore, no adverse events were reported for either AG1 or placebo over the 12-week intervention.

Conclusions: AG1® significantly increased blood vitamin C, serum folate, red blood cell folate, and decreased homocysteine in healthy adults whose fruit and vegetable intake reflects that of the average US adult.

Funding Sources: AG1; Carson City, NV 89701, USA.</sup>